Combined measurement of circulating tumor cell counts and serum tumor marker levels enhances the screening efficiency for malignant versus benign pulmonary nodules-Reference-Cited by-同舟云学术

Combined measurement of circulating tumor cell counts and serum tumor marker levels enhances the screening efficiency for malignant versus benign pulmonary nodules

Published:2022-10-25 Issue:23 Volume:13 Page:3393-3401
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Ma Guojun¹²,Yang Dawei³,Li Yang³,Li Meng¹,Li Jingtao²,Fu Jianhua²,Peng Zhongmin¹^ORCID

Affiliation:

1. Department of Thoracic Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine Shandong University Jinan China

2. Department of Thoracic Surgery Liaocheng People's Hospital Liaocheng China

3. Zhong Yuan Academy of Biological Medicine Liaocheng People's Hospital Liaocheng China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14702

Reference43 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy

3. Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives

4. Lung cancer screening with low-dose CT: a world-wide view

5. Effects of low-dose computed tomography on lung cancer screening: a systematic review, meta-analysis, and trial sequential analysis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Value of circulating tumor cell assisting low-dose computed tomography in screening pulmonary nodules based on existing liquid biopsy techniques: a systematic review with meta-analysis and trial sequential analysis;Clinical and Translational Oncology;2024-06-13

2. Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters;Cancers;2023-11-11

3. Utility of peripheral blood macrophage factor Apo10 and TKTL1 as markers in distinguishing malignant from benign lung nodules: a protocol for a prospective cohort study in Southern China;BMJ Open;2023-11

4. The development and validation of a circulating tumor cells-based integrated model for improving the indeterminate lung solid nodules diagnosis;Translational Lung Cancer Research;2023-03